PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 47/14, 9/70, 31/56	A1	(11) International Publication Number: WO 98/32465
		(43) International Publication Date: 30 July 1998 (30.07.98)

(21) International Application Number: PCT/KR98/00013

(22) International Filing Date: 23 January 1998 (23.01.98)

(30) Priority Data:
1997/2233 27 January 1997 (27.01.97) KR

(71) Applicant *(for all designated States except US)*: LG CHEMICAL LIMITED [KR/KR]; 20, Yoido-dong, Yongdungpo-gu, Seoul 150-721 (KR).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MOON, Cheol [KR/KR]; Lucky Yeonlip 3, 388-11, Doryong-dong, Yuseong-gu, Daejeon 305-340 (KR). RYOO, Je, Phil [KR/KR]; Lucky Apt., 9-202, Doryong-dong, Yuseong-gu, Daejeon 305-340 (KR). CHOI, Mi, Suk [KR/KR]; Expo Apt., 107-1104, Jeonmin-dong, Yuseong-gu, Daejeon 305-390 (KR). CHOI, Jong, Kun [KR/KR]; 1219, Samcheon-dong, Seo-gu, Daejeon 305-222 (KR).

(74) Agents: JANG, Seong, Ku et al.; 275, Yangjae-dong, Seocho-gu, Seoul 137-130 (KR).

(81) Designated States: AU, BR, CA, CN, JP, MX, RU, SG, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF STEROID DRUGS



(57) Abstract

A composition for the transdermal administration of a steroid drug containing a therapeutically effective amount of the drug; an absorption promoter consisting essentially of a diethylene glycol ether and a sorbitan ester; and a pharmaceutically acceptable adhesive matrix.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF STEROID DRUGS

FIELD OF THE INVENTION

The present invention relates to a composition for the transdermal administration of steroid drugs, wherein a mixture of a diethylene glycol ether and a sorbitan ester is used as an absorption promoter; and to a transdermal formulation containing same.

BACKGROUND OF THE INVENTION

The delivery of a drug through skin offers advantages over the conventional oral administration which is hampered by such problems as unpredictable rates of drug absorption, metabolic degradation of the drug and other adverse effects, e.g., gastrointestinal irritation caused by the drug itself or metabolites thereof. Namely, transdermal drug administration alleviates the aforementioned problems and delivers a drug at a controlled rate for an extended period of prescribed time due to increased bioavailability of the drug which is degraded in the digestive tract.

When a drug is transported through the skin, the horny layer of skin acts as a barrier against the permeation of the drug into the systemic circulation. Accordingly, various absorption promoters, or permeation enhancers, which facilitate the drug permeation through the horny layer, have been used in transdermal drug compositions. For example, U.S. Patent Nos. 4,006,218; 3,551,554; 4,568,343; 4,746,515; 4,379,454; 4,906,463; 4,440,777; 4,783,450 and 5,212,199 disclose, as such absorption promoters, dimethyl sulfoxide(DMSO), dimethylformamide, polyetyleneglycol monolaurate, glycerol monolaurate, ethanol, propyleneglycol monolaurate, eucalyptol, lecithin and sorbitan esters.

Diethyleneglycol monoethyl ether, which has been used as a solubilizer in the formulation of naproxen,

nitroglycerin, phenylbutazone and prazepam, was also reported to be effective as an absorption promoter in the transdermal administration of theophylline and prostaglandin E2 (Touitou, et al., International Journal of Pharmaceutics, 70, 159-166(1991); and Watkinson, A. et al., ibid, 74, 229-236(1991)).

Other absorption promoters disclosed in the prior art include: a mixture of linoleic acid and propyleneglycol (European Patent Publication No. 261429); and mixtures of N-(hydroxyethyl)pyrrolidone and methyl laurate, ethanol and glycerol monolaurate, diethylene glycol monoethyl ether and propyleneglycol monolaurate (US Patent Nos. 4,537,776; 4,764,379; and 4,973,468).

The conventional transdermal formulations may be divided into three types: a reservoir type, a simple matrix type and a multi-layer lamination type. The simple matrix type formulation, as disclosed in U.S. Patent Nos. 4,314,577; 4,438,139; and 4,839,174, comprises a drug dispersed in a layer made of a pressure-sensitive adhesive matrix. Such formulation can be produced at a low cost by a simple process. However, it has the problem that the rate of drug release is high in the initial stage and tapers off sharply thereafter.

Further, there exist needs to deliver a large dose of a drug over an extended period using a simple matrix-type formulation. For this purpose, there have been attempts to raise the drug content of the matrix to a level beyond the solubility of the drug in the matrix, i.e., supersaturate the matrix with the drug. However, supersaturation represents a thermodynamically unstable state and the drug in such formulation tends to form crystals. To alleviate this problem, crystal formation inhibitors, e.g., polyvinylpyrrolidone and polyvinylpyrrolidone-vinylacetate copolymer, have been used but the effectiveness thereof was observed to be marginal (Ma, X. et al., ibid, 142, 115-119(1996)).

Accordingly, there exists a need for an improved

matrix-type transdermal formulation of drugs having a steady and high rate of drug release over an extended period and also a high level of uncrystallized drug content. The present inventors have endeavored to develop an improved composition for the transdermal administration of steroid drugs, the composition having a new absorption promoter which is capable of fulfilling the above needs. It has been unexpectedly found that a diethylene glycol monoalkyl ether and a sorbitan ester, each of which has been individually known as an absorption promoter having a limited effectiveness, provide a synergistic effect when combined, i.e., a mixture of a diethylene glycol ether and a sorbitan ester has been found to be a remarkably efficient absorption promoter for the transdermal transport of steroid drugs.

SUMMARY OF THE INVENTION

It is, therefore, an object of the present invention to provide an improved composition for the transdermal administration of a steroid drug.

It is another object of the present invention to provide a transdermal formulation comprising said composition.

In accordance with one aspect of the present invention, there is provided a composition for the transdermal administration of a steroid drug, comprising: a therapeutically effective amount of the drug; an absorption promoter consisting essentially of a diethylene glycol ether and a sorbitan ester; and a pharmaceutically acceptable adhesive matrix.

BRIEF DESCRIPTION OF DRAWINGS

The above and other objects and features of the present invention will become apparent from the following description of the invention taken in conjunction with the following accompanying drawings, wherein:

Fig. 1 shows a schematic cross-sectional view of an embodiment of the inventive pharmaceutical formulation for the transdermal delivery of a steroid drug;

Fig. 2 displays the time-dependent changes in the cumulative amount of estradiol transported across the skin of a hairless mouse as a function of the absorption promoter used;

Fig. 3 depicts the time-dependent changes in the cumulative amount of norethisterone acetate transported across the skin of a hairless mouse as a function of the absorption promoter used;

Fig. 4 illustrates the time-dependent changes in the cumulative amount of norethisterone acetate transported across human cadaver skin as a function of the absorption promoter used; and

Fig. 5 exhibits the time-dependent changes in the cumulative amount of norethisterone acetate transported across human cadaver skin as a function of the contents of sorbitan monolaurate and diethylene glycol monoethyl ether.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a composition for the transdermal administration of a steroid drug, comprising: the steroid drug; a mixture of diethylene glycol ether and sorbitan ester which is used as an absorption promoter; and a pharmaceutically acceptable adhesive matrix.

Exemplary steroid drugs for use in the composition of the present invention include estrogens, e.g., estradiol, ethynyl estradiol and estradiol ester; progestogens, e.g., norethisterone, norethisterone acetate, medroxyprogesterone acetate, desogestrel, gestaten and levonorgestrel; androgens, e.g., testosterone, testosterone propionate, testosterone enanthate, testosterone cypionate, methyltestosterone and dihydroepiandrosterone; and a mixture thereof.

The total amount of the steroid drug used in the

inventive composition may range from 0.05 to 30 wt%, preferably, from 0.1 to 10 wt% based on the total weight of the composition.

The absorption promoter of the present invention is composed of a diethylene glycol monoalkylether and a sorbitan ester mixed in a weight ratio ranging from 1:4 to 4:1, preferably, from 1:2 to 2:1. Diethyleneglycol monoalkyl ethers which may be suitably used in the present invention include diethylene glycol monoethyl ether and diethylene glycol monomethyl ether, and suitable sorbitan esters include sorbitan monolaurate and sorbitan monooleate.

The total amount of the mixture of diethylene glycol ether and sorbitan ester used in the inventive composition may range from 5 to 30 wt%, preferably, from 5 to 25 wt% based on the total weight of the composition, wherein the weight ratio of said two components is kept within the aforementioned range.

The pharmaceutically acceptable adhesive matrix used in the present invention may be any of those known in the art, e.g., polyacrylate adhesives such as ethyl-, butyl- and 2-ethylhexyl acrylate, polyisobutylene and silicon rubber.

The composition of the present invention may further comprise flavoring agents, preservatives, anti-oxidants, stabilizers and pigments.

The transdermal formulation of a steroid drug in accordance with another aspect of the present invention may be constructed using: a protective backing layer which is impermeable to the steroid drug; a drug reservoir layer containing the aforementioned composition of the present invention, one side of which is laminated on the protective backing layer; and a peel layer attached to the other side of the drug reservoir layer, said peel layer being capable of protecting the composition from the environment until it is removed to bring the drug reservoir layer into contact with the skin.

The formulation of the present invention may further comprise a supplementary adhesive layer which is selected

from those known in the art, e.g., a ring-shaped adhesive layer sealably attached to the periphery of the drug reservoir layer and the protective backing layer.

Fig. 1 shows a schematic cross-sectional view of an embodiment of the transdermal formulation of the present invention, which comprises peel layer(1), drug reservoir layer(2), protective backing layer(3) and supplementary adhesive layer(4).

The inventive composition for the transdermal delivery of a steroid drug has advantages in that: it is a simple matrix-type which can be prepared at a low cost; the use of the improved absorption promoter disclosed above makes it possible to maintain a high flux of the drug for an extended period, the apparent drug permeation rate following zero-order kinetics; and the formation of drug crystals is inhibited even at a high drug loading level owing to the use of said improved absorption promoter. The dosage administered to a patient by using the composition of the present invention can be controlled by adjusting the contents of the drug and the absorption promoter.

The following Examples are intended to further illustrate the present invention without limiting its scope.

Determination of Drug Permeation Rate through Skin

The flux, or the skin permeation rate (SPR), of a drug through a skin sample was determined by the following procedure.

A skin sample, either human cadaver skin or a skin piece excised from 6 week-old female hairless mouse, was installed in Valia-Chien diffusion cell(Crown Glass, U.S.A.) such that the stratum corneum of the skin faced outward from the cell, and then a transdermal formulation containing one or more steroid drugs was fixed on the skin. 3.4 mℓ of physiological saline solution containing 40% of polyethyleneglycol 400(Sigma Scientific Co.) was added to

the cell and stirred for the whole period of experiment. Thereafter, 100μl samples of the physiological saline solution were taken periodically and subjected to high performance liquid chromatography to determine the cumulative amount of the drug transported across the skin. The skin permeation rate (SPR) of the drug through the skin was calculated by regression analysis of the time-dependent cumulative amounts of the drug($\mu g/cm^2/hr$).

The process described above was repeated 3 times and averaged to define SPR of the drug.

Reference Example 1: Preparation and Testing of Transdermal Administration Compositions containing Conventional Absorption Promoters (hairless mouse skin)

0.6 wt% of estradiol(ED), 3.0 wt% of norethisterone acetate(NETA) and an absorption promoter listed in Table 1 were added to a polyacrylate adhesive(Durotac 87-2074, National Starch Chem. Co.), and then the mixture was stirred sufficiently to dissolve the drugs in the adhesive.

The mixture thus obtained was poured onto an impermeable protective backing layer(Scotchpak 1109, 3M Co.) to coat a matrix layer having a thickness of 1000μm. The resulting material consisting of the protective backing layer coated with the matrix layer was dried in an oven by raising the temperature stepwise from 60°C to 120°C. The resulting material was cured in open air for 1 hour and a peel layer(Scotchpak 1012, 3M Co.) was laminated thereon. The resulting transdermal formulation was stored at room temperature.

The permeation rates of the drugs across the skin of hairless mouse were determined and the results are shown in Table 1 and Figs. 2 and 3.

Table 1. Permeation rates of ED and NETA across mouse skin in the presence of conventional absorption promoter

Reference Example	ED (wt%)	NETA (wt%)	Absorption Promoter (wt%)	SPR* (ED)	SPR* (NETA)
1-1	0.6	3.0	-	0.12 ±0.02	0.43 ±0.09
1-2	0.6	3.0	azone (10)	0.10 ±0.01	0.64 ±0.08
1-3	0.6	3.0	tricapryline (10)	0.16 ±0.05	0.49 ±0.10
1-4	0.6	3.0	sorbitan monolaurate (10)	1.02 ±0.05	1.87 ±0.17
1-5	0.6	3.0	squalene (10)	0.19 ±0.03	1.98 ±0.48
1-6	0.6	3.0	decanol (10)	0.11 ±0.01	0.45 ±0.05

*SPR: Skin permeation rate across the skin (mean±SD($\mu g/cm^2/hr$))

Figs. 2 and 3 show the time-dependent cumulative amounts of estradiol and norethisterone acetate transported across the skin as function of absorption promoter used.

As can be seen from Table 1 and Figs. 2 and 3, the compositions containing sorbitan monolaurate(Reference Example 1-4) and squalene (Reference Example 1-5) as the absorption promoter exhibited high permeation rates. However, crystals of the drugs were observed in each of the above Reference Examples.

Reference Example 2: Preparation and Testing of Transdermal Administration Compositions containing Conventional Absorption Promoters (human cadaver skin)

Four transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin was employed in place of the mouse skin, and 4 wt% of norethisterone acetate(NETA) was employed together with the absorption promoter listed in Table 2. The results are shown in Table 2 and Fig. 4.

Table 2. Permeation rates of NETA across human cadaver skin when conventional absorption promoters are used

Reference Example	NETA (wt%)	Absorption Promoter(wt%)	SPR
2-1	4.0	-	0.18±0.03
2-2	4.0	sorbitan monolaurate (15)	0.72±0.09
2-3	4.0	squalene (15)	0.43±0.03
2-4	4.0	diethylene glycol monoethyl ether (15)	0.52±0.04

As can be seen from Table 2 and Fig. 4, the compositions containing sorbitan monolaurate (Reference Example 2-2), squalene (Reference Example 2-3) and diethylene glycol monoethyl ether (Reference Example 2-4) as the absorption promoter enhanced the permeation rate of NETA across human cadaver skin to an extent that is significantly lower than that determined for the hairless mouse skin. Further, drug crystal formation was observed in all but Reference Example 2-4, wherein diethylene glycol monoethyl ether was employed as the absorption promoter.

Example 1 to 3 and Comparative Examples 1 to 6:

Nine transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin as well as 0.4 wt% of estradiol and 2.7 wt% of norethisterone acetate were employed together with the absorption promoters listed in Table 3.

As a positive control, a commercially available reservoir type formulation, i.e., Estragest®(EG, CibaGeigy, Swiss) was used in Comparative Example 6. The results are shown in Table 3 and Fig. 5.

Table 3. Permeation rates of ED and NETA across human cadaver skin

No.	ED (wt%)	NETA (wt%)	SML (wt%)	TC (wt%)	SPR (ED)	SPR (NETA)
Comp. Ex. 1	0.4	2.7	-	-	0.08 ±0.02	0.17 ±0.01
Comp. Ex. 2	0.4	2.7	5	-	0.19 ±0.01	0.41 ±0.05
Comp. Ex. 3	0.4	2.7	10	-	0.22 ±0.02	0.46 ±0.03
Comp. Ex. 4	0.4	2.7	15	-	0.27 ±0.06	0.51 ±0.02
Ex. 1	0.4	2.7	10	10	0.23 ±0.01	0.72 ±0.06
Ex. 2	0.4	2.7	10	5	0.23 ±0.03	0.75 ±0.06
Ex. 3	0.4	2.7	5	10	0.26 ±0.03	0.62 ±0.03
Comp. Ex. 5	0.4	2.7	-	10	0.17 ±0.04	0.35 ±0.02
Comp. Ex. 6					0.15 ±0.04	0.45 ±0.09

SML: sorbitan monolaurate,
TC: diethylene glycol monoethyl ether

As can be seen from Table 3 and Fig. 5, the inventive compositions containing a mixture of diethylene glycol monoethyl ether(TC) and sorbitan monolaurate(SML) having a TC to SML weight ratio in the range of 0.5 to 2(Examples 1, 2 and 3) as the absorption promoter exhibited markedly enhanced permeation rates of the drugs across human cadaver skin, as compared with those observed in Comparative Examples 1-6. The permeation rates follow apparent zero-

order kinetics. Further, drug crystals were not observed in Examples 1, 2 and 3.

Example 4 and Comparative Examples 7 to 10:

Five transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin and 3.5 wt% of testosterone were employed together with the absorption promoters listed Table 4.

Table 4. Permeation rates of testosterone across human cadaver skin

No.	Testosterone (wt%)	Absorption Promoter (wt%)	SPR
Comp. Ex. 7	3.5	-	0.70 ±0.32
Comp. Ex. 8	3.5	SML (20)	3.07 ±1.22
Comp. Ex. 9	3.5	propyleneglycol monolaurate (20)	2.21 ±0.04
Comp. Ex. 10	3.5	TC (20)	2.03 ±0.25
Ex. 4	3.5	TC(10) and SML(10)	3.57 ±0.77

As the results in Table 4 show, the inventive composition containing a mixture of diethylene glycol monoethyl ether(TC) and sorbitan monolaurate(SML) (Example 4) as the absorption promoter exhibited a markedly higher permeation rate than those observed when TC or SML was used alone (Comparative Examples 8 and 9).

Examples 5 to 7 and Comparative Examples 11 to 12:

Five transdermal delivery compositions were prepared and tested by the procedure of Reference Example 1, except that human cadaver skin and 0.8 wt% of estradiol were employed together with the absorption promoters listed Table 5.

Table 5. Permeation rates of estradiol across human cadaver skin as a function of the absorption promoter used

No.	ED (wt%)	Absorption Promoter (wt%)	SPR
Comp. Ex. 11	0.8	-	0.15±0.01
Comp. Ex. 12	0.8	SML (10)	0.31±0.02
Ex. 5	0.8	TC(10) and SML(2.5)	0.54±0.06
Ex. 6	0.8	TC(10) and SML(5)	0.58±0.01
Ex. 7	0.8	TC(10) and SML(10)	0.42±0.03

As the results in Table 5 show, the inventive compositions containing a mixture of diethylene glycol monoethyl ether(TC) and sorbitan monolaurate(SML) having a TC to SML ratio ranging from 1 to 4 (Example Nos. 5, 6 and 7) exhibited enhanced permeation rates estradiol through human cadaver skin.

What is claimed is:

1. A composition for the transdermal administration of a steroid drug, comprising: a therapeutically effective amount of the drug; an absorption promoter consisting essentially of a diethylene glycol ether and a sorbitan ester; and a pharmaceutically acceptable adhesive matrix.

2. The composition of claim 1, wherein the weight ratio of the diethylene glycol ether and the sorbitan ester ranges from 1:4 to 4:1.

3. The composition of claim 2, wherein the weight ratio of the diethylene glycol ether and the sorbitan ester ranges from 1:2 to 2:1.

4. The composition of claim 1, wherein the diethylene glycol ether is diethylene glycol monoethyl ether, diethylene glycol monomethyl ether or a mixture thereof.

5. The composition of claim 1, wherein the sorbitan ester is sorbitan monolaurate, sorbitan monooleate or a mixture thereof.

6. The composition of claim 1, wherein the steroid drug is an estrogen, progestogen, androgen or a mixture thereof.

7. The composition of claim 6, wherein the estrogen is estradiol, ethynyl estradiol or estradiol ester.

8. The composition of claim 6, wherein the progestogen is norethisterone, norethisterone acetate, medroxyprogesterone acetate, desogestrel, gestaten or levonorgestrel.

9. The composition of claim 6, wherein the androgen

is testosterone, testosterone propionate, testosterone enanthate, testosterone cypionate, methyltestosterone or dehydroepiandrosterone.

10. The composition of claim 1, wherein the amount of the steroid drug ranges from 0.05 to 30 wt% based on the total weight of the composition.

11. The composition of claim 10, wherein the amount of the steroid drug ranges from 0.1 to 10 wt% based on the total weight of the composition.

12. The composition of claim 1, wherein the amount of the absorption promoter ranges from 5 to 30 wt% based on the total weight of the composition.

13. The composition of claim 12, wherein the amount of the absorption promoter ranges from 5 to 25 wt% based on the total weight of the composition.

14. The composition of claim 1, wherein the adhesive matrix is a polyacrylate adhesive, polyisobutylene or silicon rubber.

15. A transdermal formulation for the transdermal administration of a steroid drug, comprising: a protective backing layer; a drug reservoir layer containing the composition of claim 1, which is placed on the protective backing layer, one side of which is laminated on the protective backing layer; and a removable peel layer attached to the other side of the drug reservoir layer.

16. The formulation of claim 15, which further comprises a supplementary adhesive layer.

Fig. 1



Fig. 2


1-1
1-2
1-3
1-4
1-5
1-6
Cumulative amount of estradiol transported across the skin(μg/cm²)
0
10
20
30
40
50
60
70
Time(hour)

Fig. 3


Cumulative amount of norethisterone acetate transported across the skin(μg/cm²)
Time(hour)
1-1
1-2
1-3
1-4
1-5
1-6
0
20
40
60
80
100
120
140
160
180
0
10
20
30
40
50
60
70

Fig. 4


Cumulative amount of norethisterone acetate transported across human cadaver skin(μg/cm²)
Time(hour)
2-1
2-2
2-3
2-4
0
10
20
30
40
50
60
70
80
0
20
40
60
80
100

Fig. 5


Cumulative amount of norethisterone acetate transported across human cadaver skin(μg/cm²)
Time(hour)
Comp. Ex. 1
Comp. Ex. 2
Comp. Ex. 3
Comp. Ex. 4
Ex. 1
Ex. 2
Ex. 3
Comp. Ex. 5
Comp. Ex. 6
0
20
40
60
80
100
120
140
160
180

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 98/00013

A. CLASSIFICATION OF SUBJECT MATTER

IPC^6: A 61 K 47/14, 9/70, 31/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC^6: A 61 K 47/14, 9/70

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIL on Questel

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93/23 083 A1 (AGOURON PHARMACEUTICALS INC.) 25 November 1993 (25.11.93), claims 1,8,17,18,30, 31,34,36; page 6, lines 13-28; page 7, lines 7-28; page 9, lines 11-18; page 10, lines 9-25;	1-6,10-13
Y	claims 1,8,17.	7-9,14-16
Y	WO 90/11 064 A1 (CYGNUS RESEARCH CORPORATION) 04 October 1990 (04.10.90), abstract; claims 1,3,5-8, 11; page 8, line 33 - page 9, line 33; page 10, lines 24-33; page 12, line 16 - page 13, line 23.	7-9,14-16
Y	US 4 321 252 A (KEITH A.D. et al.) 23 March 1982 (23.03.82), claims 1,2; column 3, lines 3-9; column 1, line 21 - column 2, line 18; example IV.	1,6,7,10,11,14
Y	EP 0 322 098 A1 (MINNESOTA MINING AND MANUFACTURING COMPANY) 28 June 1989 (28.06.89), abstract; claims 1,13; page 6, lines 35-45; page 7, lines 5-10.	1,6,7,10,11,14
A	EP 0 328 806 A2 (PACO PHARMACEUTICAL SERVICES) 23 August 1989 (23.08.89), abstract; claims 1,2,4-10; page 3, lines 38-53; page 3, line 57 - page 4, line 25; fig.1.	1,5-7,10,11,14, 15

[X] Further documents are listed in the continuation of Box C. [X] See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
27 March 1998 (27.03.98)	15 April 1998 (15.04.98)

Name and mailing address of the ISA/ AT	Authorized officer
AUSTRIAN PATENT OFFICE Kohlmarkt 8-10 A-1014 Vienna	Mazzucco
Facsimile No. 1/53424/535	Telephone No. 1/53424/437

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 98/00013

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 275 550 A1 (TEIKOKU SEIYAKU KABUSHIKI KAISHA) 27 July 1988 (27.07.88), abstract; claims 1,2,7,10,11; page 4, lines 8-19,32-35,55-56.	1,6,14,15
A	EP 0 285 563 A1 (CIBA-GEIGY AG) 05 October 1988 (05.10.88), abstract; claims 1,2; page 5, lines 28-42; page 6, lines 17-26,40-49; example 1.	1-8,10-15
A	EP 0 399 432 A2 (TAKEDA CHEMICAL INDUSTRIES, LTD.) 28 November 1990 (28.11.90), abstract; claims 1,2,4,8; page 3, lines 16-19,32-33; page 3, line 47 - page 4, line 19; page 4, lines 30-46; example 1.	1,7,9-15
A	EP 0 573 133 A1 (SCHERING AKTIENGESELLSCHAFT) 08 December 1993 (08.12.93), abstract; claims 1-8; page 2, line 48 - page 3, line 18; page 4, lines 19-47.	1,6,8,10-16

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/KR 98/00013

			IL	A0	85847	30-09-88
			IL	A1	85847	25-05-92
			IT	A0	8847798	30-03-88
			IT	A	1219896	24-05-90
			JP	A2	63258817	26-10-88
			JP	B4	6051623	06-07-94
			KR	B1	9609648	23-07-96
			LU	A	87184	06-04-89
			NL	A	8800836	01-11-88
			NZ	A	224115	29-01-90
			PH	A	24549	03-08-90
			PT	A	87125	01-04-88
			PT	B	87125	31-07-92
			SE	A0	8801185	30-03-88
			SE	A	8801185	01-10-89
			US	A	4913905	03-04-90
			US	A	5128124	07-07-92
			ZA	A	8802326	30-11-88
EP A2	399432	28-11-90	AT	E	107517	15-07-94
			CA	AA	2017442	25-11-90
			DE	C0	69010076	28-07-94
			DE	T2	69010076	08-12-94
			EP	A3	399432	22-05-91
			EP	B1	399432	22-06-94
			US	A	5362497	08-11-94
			JP	A2	3072416	27-03-91
EP A1	573133	08-12-93	AT	E	132751	15-01-96
			AU	A1	43747/89	03-05-90
			AU	A1	30011/92	11-02-93
			AU	A1	20596/95	31-08-95
			CA	AA	2001618	27-04-90
			CN	A	1042075	16-05-90
			CZ	A3	8906089	17-02-93
			CZ	B6	277870	17-03-93
			DE	A1	3910578	04-10-90
			DE	C0	58909570	22-02-96
			DK	A	1385/90	06-06-90
			DK	A0	1385/90	06-06-90
			EP	A1	370220	30-05-90
			EP	A1	394429	31-10-90
			EP	B1	370220	10-01-96
			EP	B1	394429	10-01-96
			ES	T3	2081823	16-03-96
			FI	A0	903213	26-06-90
			HU	A0	896546	28-12-90
			HU	A2	55634	28-06-91
			HU	B	210549	29-05-95
			IL	A0	92007	12-07-90
			IL	A1	92007	08-12-95
			JP	T2	3502700	20-06-91
			MX	B	173621	18-03-94
			NO	A	902840	26-06-90
			NO	A	951592	26-06-90
			NO	A0	902840	26-06-90
			NO	A0	951592	26-04-95
			NO	B	180567	03-02-97
			NO	C	180567	14-05-97
			PL	A1	287526	21-10-91
			PL	B1	162400	30-11-93
			PL	B1	162410	30-11-93
			PT	A	92131	30-04-90
			PT	B	92131	30-06-95
			RU	C1	2044541	27-09-95
			SK	B6	278438	07-05-95
			SK	A3	6089/89	07-05-97
			WO	A1	9004397	03-05-90
			DD	A5	286293	24-01-91
			DE	A1	3836862	03-05-90
			ZA	A	8908201	27-03-91

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/KR 98/00013

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9323083	25-11-93	AU A1 42828/93	13-12-93
		EP A1 641221	08-03-95
		JP T2 7508976	05-10-95
		US A 5314685	24-05-94
WO A1 9011064	04-10-90	AT E 156995	15-09-97
		AU A1 54174/90	22-10-90
		AU B2 629331	01-10-92
		CA AA 2012875	22-09-90
		CA C 2012875	05-12-95
		DE C0 69031309	25-09-97
		DE T2 69031309	08-01-98
		EP A1 464150	08-01-92
		EP A4 464150	14-04-93
		EP B1 464150	20-08-97
		FI A0 914391	18-09-91
		JP T2 4505157	10-09-92
		JP B2 2550441	06-11-96
		KR B1 9510324	14-09-95
		US A 4973468	27-11-90
		US A 5063227	01-10-91
		US A 5059426	22-10-91
US A 4321252	23-03-82	JP A2 55094316	17-07-80
		JP B4 1021128	19-04-89
		AT E 7266	15-05-84
		AT E 12731	15-04-85
		AU A1 54452/80	17-07-80
		AU B2 [illegible]5330	06-10-83
		CA A1 1134365	16-11-82
		DE C0 3067659	07-06-84
		DE C0 3070548	24-04-85
		DK A 63/80	14-07-80
		DK A 1900/87	13-04-87
		DK A0 1900/87	13-04-87
		DK B 155776	16-05-89
		DK C 155776	09-10-89
		EP A2 13606	23-07-80
		EP A3 13606	07-01-81
		EP A1 40861	02-12-81
		EP A1 40862	02-12-81
		EP B1 13606	02-05-84
		EP B1 40861	17-04-85
		ES A1 487588	16-12-80
		ES A3 487588	16-01-81
		ES A1 8101894	01-04-81
		FI A 800064	12-07-80
		FI B 76690	31-08-88
		FI C 76690	12-12-88
		GR A 74069	06-06-84
		IE B 50567	14-05-86
		IL A0 59064	30-04-80
		IL A1 59064	30-12-83
		NO A 800054	14-07-80
		NO A 841160	14-07-80
		NO B 156234	11-05-87
		NO C 156234	19-08-87
		NO B 166688	21-05-91
		NO C 166688	28-08-91
		NZ A 192532	19-10-84
		PT A 70679	01-01-80
		US A 4289749	15-09-81
		US A 4291015	22-09-81
		US A 4292301	29-09-81
		US A 4292302	29-09-81
		US A 4292303	29-09-81
		US A 4294820	13-10-81
		US A 4466955	21-08-84
		US A 4470963	11-09-84
		US A 4472372	18-09-84
		HU B 183065	28-04-84

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/KR 98/00013

			KR	A	8301816	12-09-83
			ZA	A	8000073	29-07-81
			US	A	4438139	20-03-81
			US	A	4291014	22-09-81
			US	A	4460562	17-07-84
			US	A	4492685	08-01-85
			US	A	4579731	01-04-86
			JP	A2	57018629	30-01-82
			AU	A1	74151/81	02-02-82
			BE	A1	889549	03-11-81
			CA	A1	1163559	14-03-84
			CH	A	658597	28-11-86
			DE	T	3152182	10-02-83
			FR	A1	2486397	15-01-82
			GB	A1	2089210	23-06-82
			GB	B2	2089210	05-09-84
			JP	T2	57500980	03-06-82
			SE	B	447448	17-11-86
			SE	C	447448	26-02-87
			WO	A1	8200099	21-01-82
			NO	A	820722	08-03-82
			NO	B	153638	20-01-86
			NO	C	153638	07-05-86
			SE	A	8201337	04-03-82
			AU	A1	74502/81	19-01-82
			CA	A1	1163195	06-03-84
			EP	A1	55295	07-07-82
			JP	T2	57500831	13-05-82
			WO	A1	8200005	07-01-82
			NL	A	8120270	01-06-82
			AT	E	20311	15-06-86
			CA	A1	1200205	04-02-86
			DE	C0	3271647	17-07-86
			EP	A1	82880	06-07-83
			EP	B1	82880	11-06-86
			JP	T2	58501034	30-06-83
			WO	A1	8300092	20-01-83
			JP	A2	58035691	12-03-83
			IT	A0	82198433	24-03-82
			US	A	4482533	13-11-84
EP A1	322098	28-06-89	CA	A1	1333114	15-11-94
			DE	C0	3850558	11-08-94
			DE	T2	3850558	02-02-95
			EP	B1	322098	06-07-94
			JP	A2	11156384	19-06-89
			JP	B2	2525179	02-07-97
			US	A	5225473	06-07-93
EP A2	328806	23-08-89	AU	A1	19177/88	17-08-89
			EP	A3	328806	07-02-90
			IL	A0	87135	30-12-88
			JP	A2	2003607	09-01-90
			US	A	4906475	06-03-90
EP A1	275550	27-07-88	DE	C0	3785571	27-05-93
			DE	T2	3785571	12-08-93
			EP	B1	275550	21-04-93
			JP	A2	63160649	04-07-88
			JP	B4	7044940	17-05-95
			US	A	4900554	13-02-90
			CA	A1	1327314	01-03-94
EP A1	285563	05-10-88	AT	A	874/88	15-05-91
			AT	B	393624	25-11-91
			AT	E	75402	15-05-92
			AU	A1	15323/88	13-10-88
			AU	B2	612360	11-07-91
			BE	AF	1000696	14-03-89
			CA	A1	1300021	05-05-92
			CH	A	674618	29-06-90
			DE	A1	3810896	20-10-88
			DE	C0	3870504	04-06-92
			DK	A0	1796/88	30-03-88
			DK	A	1796/88	03-10-88
			EP	B1	285563	29-04-92
			ES	AF	2010745	01-12-89
			ES	T3	2032221	16-01-93
			FR	A1	2614324	07-10-88
			GB	A0	8807399	05-05-88
			GB	A1	2208147	09-03-89
			GB	B2	2208147	02-01-91
			GR	A	88100213	31-01-89
			IE	B	61114	05-10-94

Form PCT/ISA/210 (patent family annex) (July 1992)